Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Texas
  • El Paso


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Observation vs Early Removal of LAMS in EUS Guided Cholecystoenterostomy
    NCT04167072
    Conditions:   Cholecystitis, Acute;   Cholecystitis; Gallstone
    Intervention:   Procedure: Stent removal
    Sponsor:   Texas Tech University Health Sciences Center, El Paso
    Recruiting
  • A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy
    NCT03937505
    Condition:   Ureter Injury
    Interventions:   Drug: IS-001;   Drug: No treatment
    Sponsor:   Intuitive Surgical
    Recruiting
  • Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Pancreatic Tumors.
    NCT03264092
    Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms
    Intervention:   Procedure: Endoscopic ultrasound guided fine needle biopsy
    Sponsor:   Texas Tech University Health Sciences Center, El Paso
    Recruiting
  • Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
    NCT03188991
    Condition:   Pancreatic Mucinous-Cystic Neoplasm
    Intervention:   Drug: NanoPac®
    Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
    Recruiting
  • Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
    NCT03077685
    Condition:   Locally Advanced Pancreatic Adenocarcinoma
    Intervention:   Drug: NanoPac®
    Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
    Recruiting
  • Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination
    NCT03209713
    Condition:   Parents
    Interventions:   Behavioral: HPV Vaccine Education;   Behavioral: Text Messaging Reminder
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  • Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
    NCT04106726
    Condition:   Facial Rosacea
    Interventions:   Drug: Soolantra® Ivermectin cream 1%;   Drug: Ivermectin cream 1%;   Drug: Placebo for Ivermectin cream 1%
    Sponsors:   Zydus Worldwide DMCC;   Catawba Research, LLC
    Recruiting
  • A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
    NCT03990363
    Condition:   Chronic Kidney Disease
    Interventions:   Drug: Verinurad;   Drug: Allopurinol;   Drug: Placebo for Verinurad;   Drug: Placebo for Allopurinol
    Sponsor:   AstraZeneca
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
    NCT03290508
    Condition:   Prostate Cancer
    Intervention:   Diagnostic Test: Prolaris Testing
    Sponsor:   Myriad Genetic Laboratories, Inc.
    Recruiting
  • Buspirone for Early Satiety and Symptoms of Gastroparesis
    NCT03587142
    Condition:   Gastroparesis
    Interventions:   Drug: Buspirone;   Drug: Placebo
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
    NCT04124705
    Conditions:   Hypothyroidism;   Thyroid Disease;   Euthyroid;   Thyroid Gland;   Thyroid Hormones
    Interventions:   Drug: Armour® Thyroid;   Drug: Synthetic T4
    Sponsor:   Allergan
    Recruiting
  • A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
    NCT04089735
    Condition:   Ocular Inflammation and Pain
    Interventions:   Drug: APP13007, 0.05%;   Drug: APP13007, 0.1%;   Drug: APP13007 Placebo, 0.05%;   Drug: APP13007 Placebo, 0.1%
    Sponsor:   Formosa Pharmaceuticals, Inc.
    Recruiting
  • CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
    NCT04053543
    Condition:   PAH
    Intervention:   Drug: CXA-10
    Sponsors:   Complexa, Inc.;   Medpace, Inc.;   Innovative Analytics;   Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    Recruiting
  • Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
    NCT04026165
    Condition:   Diabetic Kidney Disease
    Interventions:   Drug: SEL;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting
  • An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
    NCT03943147
    Condition:   Lupus Nephritis
    Interventions:   Drug: BMS-986165;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
    NCT03931785
    Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
    Interventions:   Drug: MD-7246;   Drug: Placebo
    Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
    Recruiting
  • A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
    NCT03891524
    Condition:   Arthroplasty, Replacement, Knee
    Interventions:   Drug: JNJ-70033093 25 mg;   Drug: JNJ-70033093 50 mg;   Drug: JNJ-70033093 100 mg;   Drug: JNJ-70033093 200 mg;   Drug: Placebo;   Drug: Enoxaparin 40 mg
    Sponsors:   Janssen Research & Development, LLC;   Bristol-Myers Squibb
    Recruiting
  • Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
    NCT03874715
    Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: Insulin Aspart SAR341402;   Drug: Insulin Aspart;   Drug: Insulin glargine U100
    Sponsor:   Sanofi
    Recruiting
  • A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
    NCT03819153
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy
    NCT03804879
    Condition:   Diabetic Nephropathy
    Interventions:   Drug: LMB763;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa
    NCT03799627
    Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
    Interventions:   Drug: Vadadustat;   Drug: Epoetin Alfa;   Drug: Vadadustat TIW
    Sponsor:   Akebia Therapeutics
    Recruiting
  • End-stage Renal Disease (ESRD) Pilot Study
    NCT03787368
    Condition:   Renal Dialysis
    Interventions:   Drug: BAY1213790;   Drug: 0.9% sodium chloride solution
    Sponsor:   Bayer
    Recruiting
  • A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
    NCT03766581
    Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
    Interventions:   Drug: BMS-986177;   Other: Placebo;   Drug: Clopidogrel;   Drug: Aspirin
    Sponsors:   Bristol-Myers Squibb;   Janssen, LP
    Recruiting
  • A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
    NCT03697109
    Condition:   Cushing Syndrome
    Interventions:   Drug: Relacorilant;   Other: Placebo
    Sponsor:   Corcept Therapeutics
    Recruiting
  • GB001 in Adult Subjects With Moderate to Severe Asthma
    NCT03683576
    Condition:   Asthma
    Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
    Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
    Recruiting
  • Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
    NCT03650114
    Condition:   Relapsing Multiple Sclerosis
    Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Safety and Efficacy of KPI-121 in Subjects With DED
    NCT03616899
    Condition:   Kerato Conjunctivitis Sicca
    Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
    Sponsor:   Kala Pharmaceuticals, Inc.
    Recruiting
  • Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
    NCT03598036
    Condition:   Focal Segmental Glomerulosclerosis
    Intervention:   Drug: Voclosporin
    Sponsor:   Aurinia Pharmaceuticals Inc.
    Recruiting
  • EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
    NCT03594110
    Condition:   Chronic Kidney Disease
    Interventions:   Drug: Empagliflozin;   Drug: Matching placebo
    Sponsors:   Boehringer Ingelheim;   Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead);   Eli Lilly and Company
    Recruiting
  • Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
    NCT03561883
    Condition:   Gastroesophageal Reflux Disease (GERD)
    Interventions:   Drug: IW-3718;   Drug: placebo
    Sponsor:   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
    NCT03544229
    Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
    Interventions:   Drug: TAK-906 Maleate;   Drug: TAK-906 Maleate Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD
    NCT03496623
    Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Inhaled treprostinil solution;   Drug: Placebo solution
    Sponsor:   United Therapeutics
    Recruiting
  • PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
    NCT03449524
    Condition:   PAH
    Interventions:   Drug: 75mg CXA-10;   Drug: 150mg CXA-10;   Other: Placebo
    Sponsors:   Complexa, Inc.;   Medpace, Inc.;   Philips Healthcare;   Cardiovascular Clinical Science Foundation;   MicroConstants;   Innovative Analytics;   Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    Recruiting
  • Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02
    NCT03426345
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03422510
    Condition:   Primary Focal Segmental Glomerulosclerosis
    Intervention:   Drug: CXA-10
    Sponsors:   Complexa, Inc.;   Kidney Research Network, formerly NephCure Accelerating Cures Institute;   Medpace, Inc.;   MicroConstants;   Arkana Labs;   NephCure Kidney International
    Recruiting
  • Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
    NCT03409107
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat (GSK1278863);   Drug: Placebo;   Drug: Iron therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
    NCT03395197
    Condition:   mCRPC
    Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
    Sponsors:   Pfizer;   Astellas Pharma Inc
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
    NCT03383146
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
    NCT03377491
    Condition:   Pancreas Adenocarcinoma
    Interventions:   Device: NovoTTF-100L(P);   Drug: Gemcitabine;   Drug: nab paclitaxel
    Sponsor:   NovoCure Ltd.
    Recruiting
  • Palbociclib in Real World Practice
    NCT03280303
    Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting
  • Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
    NCT03175744
    Condition:   Critical Limb Ischemia
    Interventions:   Device: Stellarex DCB;   Device: PTA Catheter
    Sponsor:   Spectranetics Corporation
    Recruiting
  • An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)
    NCT03173092
    Condition:   Multiple Myeloma
    Interventions:   Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
    NCT03068130
    Condition:   Pulmonary Hypertension
    Intervention:   Drug: Bardoxolone methyl
    Sponsor:   Reata Pharmaceuticals, Inc.
    Recruiting
  • A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
    NCT03036150
    Condition:   Chronic Kidney Disease
    Interventions:   Drug: Dapagliflozin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
    NCT03022825
    Condition:   Bladder Cancer
    Interventions:   Drug: ALT-803;   Drug: BCG
    Sponsor:   Altor BioScience
    Recruiting
  • TARGET Post-Approval Study
    NCT02800863
    Condition:   Complex Regional Pain Syndrome (CRPS)
    Interventions:   Device: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System);   Device: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Dose Ranging Study Evaluating Efficacy and Safety of NI-03
    NCT02693093
    Condition:   Chronic Pancreatitis
    Interventions:   Drug: NI-03;   Drug: Placebo
    Sponsor:   Kangen Pharmaceuticals, Inc
    Recruiting
  • The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
    NCT02675114
    Condition:   Aortic Stenosis
    Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
    Sponsor:   Edwards Lifesciences
    Recruiting
  • A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
    NCT02636946
    Conditions:   Glaucoma;   Open-Angle Ocular Hypertension
    Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
    Sponsor:   Allergan
    Recruiting
  • Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
    NCT02630316
    Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
    Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
    Sponsor:   United Therapeutics
    Recruiting
  • CLUSTER Trial for Outbreak Detection and Response
    NCT04053075
    Condition:   Cluster Detection
    Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
    Recruiting
  • A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
    NCT03691649
    Condition:   Glaucoma and Ocular Hypertension
    Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
    Sponsor:   Santen Inc.
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
    NCT03661866
    Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
    NCT03595124
    Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
    NCT03580356
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03493685
    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
    NCT02717507
    Condition:   Cancer Survivor
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Registry for Patients With Chronic Hypoparathyroidism
    NCT01922440
    Condition:   Chronic Hypoparathyroidism
    Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
    Sponsor:   Shire
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC